Calendar

««Mar 2010»»
SMTWTFS
  123456
78910111213
14151617181920
21222324252627
28293031
  More

Search Box

 

cbt and mindfulness

Mailing List

RSS Feeds








Add to Jamespot
Widgetize!

Translate

Disclaimer

All content within Anxiety Insights is provided for general information only, and should not be treated as a substitute for the medical advice of your doctor or other health care professional.

Anxiety Insights is not responsible or liable for any diagnosis made by a reader based on the content of this website.

Anxiety Insights is not liable for the contents of any external internet sites listed, nor does it endorse any commercial product or service mentioned or advised on any of the sites.

Always consult your doctor if you are in any way concerned about your health.

Recommended links

Depression is Real's Down & Up Show
Weekly audio-casts from the Depression Is Real Coalition

Teen Drug Abuse Intervention
Help fight teen drug abuse, we provide information to help fight teen drug abuse by prevention and intervention.
www.teendrugabuse.us


we support

Kiva.org - micro loans that change lives

Moving a Nation to Care : Post Traumatic Stress Disorder and America's Returning Troops, by Ilona Meagher

No Longer Lonely.com

"just don't smoke"


"Don't smoke, whatever you do, just don't smoke."
                        Yul Brynner

Hit Counter

Total: 3,606,748
since: 14 May 2006

Abstract: Quetiapine addition in obsessive-compulsive disorder

posted Friday, 26 January 2007

Biol Psychiatry. 2007 Feb 1;61(3):412-4.

Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors?

Denys D, Fineberg N, Carey PD, Stein DJ.

The Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands.

BACKGROUND: The purpose of this study was to assess the effect of type and dose of serotonin reuptake inhibitors (SRIs) on treatment outcome in quetiapine [Seroquel®] addition trials for obsessive-compulsive disorder.

METHODS: Results from all available, double blind, placebo-controlled quetiapine addition trials were pooled. Treatment outcome was assessed in a sample of 102 patients by change from baseline to end point on the Yale-Brown obsessive-compulsive scale (Y-BOCS).

RESULTS: Quetiapine addition was superior with a mean Y-BOCS decrease of 6.8 +/- 6.7 compared with placebo with a decrease of 3.9 +/- 6.5 points. Patients with the lowest SRI dose showed the largest decrease on the Y-BOCS (11.6 +/- 7.7) compared with patients with the median dose (6.1 +/- 6.1) and highest dose (5.9 +/- 6.4).

CONCLUSIONS: We found a superior response in the quetiapine addition group compared with the placebo group. The best response was achieved with the combination of clomipramine, fluoxetine, and fluvoxamine and with the lowest SRI doses.

PMID: 17241831 [PubMed - in process]

(Text has been reformatted for clarity; ed.)

Source...

tags:    

links: digg this    del.icio.us    technorati    reddit